SUMMARY
The ASCO Annual Meeting was held from 2–6 June 2023 in hybrid (live and virtual) format. During this meeting, neoadjuvant immunotherapy strategies are further entering the field of nasopharyngeal carcinoma (NPC) and head and neck squamous cell carcinoma (HNSCC). Immunotherapy + chemotherapy gains an overall survival (OS) benefit in first-line recurrent/metastatic (R/M) NPC. Promising chemotherapy-free regimens are at the horizon in first- and second-line treatment of R/M HNSCC, though more studies in larger patient populations are needed. Treating salivary gland tumours with prostate cancer products was not successful in two studies shown during the meeting.
In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(Belg J Med Oncol 2023;17(5):157–68)
